Annual report
4543.TEDINET S100OS1S
Period2021-04-01 → 2022-03-31
Filed2022-07-26
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Amends S100OAR8. Amended by S100OSC2 (2022-07-26).
Key figures · 169
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥703.3bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥613.8bn | 2020-04-01 → 2021-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥628.9bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥599.5bn | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥587.8bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥116.0bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥98.4bn | 2020-04-01 → 2021-03-31 | Cons. | Operating profit loss IFRS |
| Ordinary income | ¥88.5bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥114.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥97.1bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥106.5bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥102.7bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥106.6bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥88.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥77.3bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥85.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥79.5bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥75.6bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥91.3bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥88.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥77.2bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥1.47T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.35T | at 2021-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.24T | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.12T | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.06T | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.08T | at 2018-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥461.4bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥494.5bn | at 2021-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥856.7bn | at 2021-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥754.9bn | at 2020-03-31d | Cons. | Equity IFRS |
| Net assets / equity | ¥535.9bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Equity (owners) | ¥1.01T | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥856.7bn | at 2021-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥754.8bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥698.0bn | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥550.3bn | at 2018-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥205.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥200.8bn | at 2021-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥166.9bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥123.0bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥167.8bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥141.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥121.5bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥117.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥93.6bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥112.4bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥114.6bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥78.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥85.3bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥84.7bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥74.8bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥42.2bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥44.1bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥70.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥7.4bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥14.0bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥67.5bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥3.9bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.1bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥117.45 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥102.33 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥113.96 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥108.7 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥107.28 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥129.56 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥117.38 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥102.11 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥112.61 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥104.97 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥99.91 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥121.03 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,338.46 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,133.13 | at 2021-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,003.36 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥939.6 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥756.49 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥777.94 | at 2018-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 68.7% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 63.4% | at 2021-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 60.8% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.3% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.6% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.9% | at 2018-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 9.5% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 9.6% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.7% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.7% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 14.8% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.5% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 28,294 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 26,482 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 26,438 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 25,378 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 23,319 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥341.4bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥316.4bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥319.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥307.0bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥292.9bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥59.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥51.9bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥79.4bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥65.3bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥80.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥72.9bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥85.4bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥78.8bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥65.8bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥62.8bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥52.0bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥65.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥58.1bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥64.5bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.28T | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥1.26T | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥1.15T | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.04T | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.03T | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥517.3bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥537.5bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥765.4bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥725.2bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥687.2bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥624.9bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥516.8bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥98.3bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥107.4bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥83.04 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.89 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.31 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥79.47 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.51 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥82.99 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥68.74 | 2020-04-01 → 2021-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥86.29 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥76.78 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥85.22 | 2017-04-01 → 2018-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥34 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥29 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,011.08 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥958.26 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥912.44 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥840.16 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥729.63 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 59.6% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.4% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.9% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.2% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.4% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.2% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 759,521,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 759,521,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 759,521,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 379,760,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 379,760,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 5,377 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 5,247 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 5,087 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 4,908 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 4,781 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥4.4bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2022-03-31 | ¥251m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥3.2bn |
| Blood And Cell Technologies Companyreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥17.6bn |
| Blood And Cell Technologies Companyreportable segment | employees | at 2022-03-31 | 6366 pure |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥120.6bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥20.8bn |
| Cardiac And Vascular Companyreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥32.0bn |
| Cardiac And Vascular Companyreportable segment | employees | at 2022-03-31 | 14780 pure |
| Cardiac And Vascular Companyreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥397.1bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥93.2bn |
| Medical Care Solutions Companyreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥15.3bn |
| Medical Care Solutions Companyreportable segment | employees | at 2022-03-31 | 6115 pure |
| Medical Care Solutions Companyreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥185.3bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥23.6bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥64.8bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥703.1bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥137.7bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥4.2bn |
| Reconciling Itemsreconciling | revenue external | 2020-04-01 → 2021-03-31 | ¥256m |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥3.3bn |
| Blood And Cell Technologies Companyreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥23.3bn |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥109.5bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥19.1bn |
| Cardiac And Vascular Companyreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥34.6bn |
| Cardiac And Vascular Companyreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥328.5bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥74.4bn |
| Medical Care Solutions Companyreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥15.1bn |
| Medical Care Solutions Companyreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥175.5bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥25.7bn |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥73.0bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥613.6bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥119.2bn |
| Blood And Cell Technologies Companyreportable segment | employees | at 2022-03-31 | 260 pure |
| Cardiac And Vascular Companyreportable segment | employees | at 2022-03-31 | 1791 pure |
| Medical Care Solutions Companyreportable segment | employees | at 2022-03-31 | 2364 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,799
| Item | Context | Value | Unit |
|---|---|---|---|
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.020 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 12969000 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.017 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 11865000 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.016 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 11712000 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.016 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 10833000 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.014 | |
| Number of shares held | CurrentYearInstant | 377307000 | |
| Shareholding ratio | CurrentYearInstant | 0.499 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 3194900 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 7561778 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 756177800 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 148340 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 759521040 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 7561778 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 3194900 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 3194900 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0042 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 3194900 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 3194900 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0042 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row1Member | 12100000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 16 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row2Member | 13613000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row2Member | 18 | |
| Number of male directors and other officers | FilingDateInstant | 10 | |
| Number of female directors and other officers | FilingDateInstant | 1 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.09 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01630-000TakagiToshiakiMember | 39325 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01630-000SatoShinjiroMember | 61496 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01630-000HatanoShojiMember | 21790 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01630-000NishikawaKyoMember | 16302 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01630-000HiroseKazunoriMember | 9879 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01630-000KurodaYukikoMember | 607 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01630-000NishiHidenoriMember | 1071 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01630-000OzawaKeiyaMember | 248 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01630-000ShibazakiTakanoriMember | 16145 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01630-000NakamuraMasaichiMember | 1115 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01630-000UnoSoichiroMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 167978 | |
| Audit fees reporting company | Prior1YearDuration | 123000000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |